ScholarIQanswers from OpenAlex

Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience

PaperCitations, authors & open-access status

Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience have?

ScholarIQcitation count

Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience has 14 citations in the OpenAlex counts ScholarIQ stores.

When was Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience published?

ScholarIQyear

Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience has 2023 year in the ScholarIQ index.

What is the open-access status of Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience?

ScholarIQoa status

Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience has gold oa status in the ScholarIQ index.

What is the DOI of Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience?

ScholarIQdoi

The DOI for Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience is on the source record.

What is the PMID of Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience?

ScholarIQpmid

The PMID for Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience is on the source record.

What is the OpenAlex record for Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience?

ScholarIQopenalex

The OpenAlex for Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial